November 1, 2024
Diabetic Retinopathy Articles
October 19, 2024
Eylea HD Data Discussion With Drs. Kaiser and Do at AAO
By Peter K. Kaiser, MD, Diana V. Do, MD
October 18, 2024
Faricimab Effective in Underrepresented DME Patients
By Jim Gallagher, senior managing editor
October 18, 2024
First Top-Line Data from ELEVATUM on Faricimab Treatment in Underrepresented Minority Populations
By Jeremiah Brown Jr., MS, MD , Michael A. Singer, MD
October 1, 2024
Clinical Trial Update October 2024
September 1, 2024
Clinical Trial Update September 2024
July 23, 2024
Two-year Data on Susvimo Reported at ASRS
July 18, 2024
Interim Phase 1 HELIOS Trial Data of Axpaxli for NPDR Presented at ASRS
By Jennifer Ford, senior managing editor
July 17, 2024
Outcomes of Faricimab in DME Study Presented at ASRS
July 10, 2024
Vabysmo Prefilled Syringe Receives FDA Approval
July 10, 2024
APX3330 Shows Promise in Slowing DR Progression
July 10, 2024
Faricimab Shows Durable Efficacy and Safety in 2-Year DME Study
July 10, 2024
Cardiovascular Health Linked to Lower Retinopathy Risk in US Adults
July 1, 2024
FDA Clears AI Device for Portable Diabetic Retinopathy Screening
By Rochelle Nataloni, contributing writer
July 1, 2024
Ocular Telehealth Program Enables Remote Retina Disease Screening
By Rochelle Nataloni, contributing writer
July 1, 2024
Study Highlights Demographic Disparities in Diabetic Retinopathy Care
By Rochelle Nataloni, contributing writer
July 1, 2024
Clinical Trial Update July/August 2024
July 1, 2024
ANI Pharmaceuticals to Acquire Alimera Sciences
July 1, 2024
Clinical Implications of Associations Between Diabetic Retinopathy and Age-related Macular Degeneration
By Deborah Li, BA, Nicholas Fazio, BS, Michael Wolek, MD, et al.
June 1, 2024
Upfront: New Efforts to Halt Diabetic Eye Disease
By Peter K. Kaiser, MD
June 1, 2024
Ocular Therapeutix Reports Positive Top-line Phase 1 Data for Axpaxli
By Rochelle Nataloni, contributing writer
June 1, 2024
DME Treatment AG-73305 Found Safe, Effective in Phase 2b Trial
By Jim Gallagher, senior managing editor
June 1, 2024
Impact of Glycemic Control and Hypoglycemia on Diabetic Retinopathy
By Deborah Li, BA, Andre Galenchik-Chan, BS, Diane Chernoff, BA , et al.
June 1, 2024
Coding: Medicare Considerations of Compounded Drugs
By Brandy H. Sperry, COMT, COE, CPC, CPMA
June 1, 2024
Controversies in Care: Chlorhexidine as an Alternative to Povidone-iodine for Antisepsis Before Intravitreal Injection
By Michael Colucciello, MD, Jason Fan, MD, PhD, Harry W. Flynn Jr., MD, et al.
June 1, 2024
The Evolution of Clinical Trial Endpoints for Diabetic Retinopathy
By David R. Lally, MD, Jay S. Pepose, MD, PhD, George N. Magrath, MD, MBA, MS, et al.
June 1, 2024
The Landscape of Gene Therapy for Diabetic Retinopathy
By Priya Vakharia, MD, David A. Eichenbaum, MD
June 1, 2024
The Continuing Evolution of Diabetic Retinal Disease Staging
By Daniel F. Kiernan, MD, FACS
June 1, 2024
Clinical Trial Update June 2024
June 1, 2024
FDA Approves First Biosimilars to Eylea
By Jim Gallagher, senior managing editor
May 1, 2024
Clinical Trial Update May 2024
May 1, 2024
New Product Applications: Lengthening the Time Between Treatments
By Karen Appold, contributing writer
May 1, 2024
Subspecialty News May 2024
By Rochelle Nataloni, contributing writer
April 29, 2024
AMARONE Shows Promising Outcomes for a Novel Treatment Pathway in DME and nAMD
By Charles C. Wykoff, MD, PhD, Michael A. Singer, MD
April 1, 2024
Upfront: Innovations in VEGF Inhibition Delivery
By Peter K. Kaiser, MD
April 1, 2024
Clinical Trial Update April 2024
April 1, 2024
Subspecialty News April 2024
By Rochelle Nataloni, contributing writer
April 1, 2024
Tyrosine Kinase Inhibitors for Wet AMD and Diabetic Retinopathy
By Nikhil Das, MD, Katherine E. Talcott, MD
April 1, 2024
Nesvategrast Fails to Meet Primary Efficacy Endpoint in DR:EAM Trial
By Jim Gallagher, senior managing editor
March 1, 2024
Clinical Trial Update March 2024
March 1, 2024
Subspecialty News March 2024
By Rochelle Nataloni, contributing writer
February 16, 2024
Retinal Physician eUpdate - February 16, 2024
By Steve Lenier
January 1, 2024
Show Daily Coverage From the American Academy of Ophthalmology 2023 Annual Meeting
By Steve Lenier
January 1, 2024
Clinical Trial Update January/February 2024
November 1, 2023
Detection of Peripheral Retinal Nonperfusion in Diabetic Patients Using Ultrawidefield Imaging
By Ali Erginay, MD
November 1, 2023
SUBSPECIALTY NEWS: Ryzumvi approved, positive gene therapy data, Syfovre receives J code, and more.
By Rochelle Nataloni, contributing writer
November 1, 2023
Clinical Trial Update November/December 2023
October 1, 2023
The Diabetic Retinopathy Pipeline
By Nathalie E. Perez, BS, Lauren C. Kiryakoza, MD, Jayanth Sridhar, MD
October 1, 2023
A 2023 Update on Treatment Paradigms and Options for Nonproliferative Diabetic Retinopathy
By Saagar A. Pandit, MD, MPH, Michael Klufas, MD
October 1, 2023
Neurotrophic Keratitis in Diabetic Patients Following Retinal Surgery
By Eric A. Lovett Jr., BS, MBA, Matthew R. Starr, MD, AJAY E. KURIYAN, MD, MS
October 1, 2023
Updates in the Diabetic Retinopathy Screening Landscape
By Ruby Hollinger, BA, Jayanth Sridhar, MD
October 1, 2023
UPFRONT: The Global Burden of Diabetes
By Peter K. Kaiser, MD
October 1, 2023
SUBSPECIALTY NEWS: Biosimilar FDA application hits roadblock, Apellis provides guidance on Syfovre use, and more.
By Rochelle Nataloni, contributing writer
October 1, 2023
NEW PRODUCT APPLICATIONS: Optos Retinal Imaging System Offers New Color Modality
By Karen Appold, contributing writer
October 1, 2023
Clinical Trial Update October 2023
September 1, 2023
Bispecific Antibodies in Retina Therapies
By René Rückert, MD, MBA, Gemmy Cheung Chui Ming, FRCOphth, Marion R. Munk, MD, PhD, FEBO
September 1, 2023
The Current Landscape of Anti-VEGF Biosimilars
By Angela S. Li, MD, Sharon Fekrat, MD, FASRS
September 1, 2023
SUBSPECIALTY NEWS: Izervay FDA approval, ReST committee updates on Syfovre, and more.
By Rochelle Nataloni, contributing writer
September 1, 2023
Clinical Trial Update September 2023
July 1, 2023
SUBSPECIALTY NEWS: Mydriasis spray approved, laser and imaging devices cleared, new AI technology, and more.
By Rochelle Nataloni, contributing writer
July 1, 2023
Clinical Trial Update July/August 2023
June 1, 2023
SUBSPECIALTY NEWS: New product launches in laser and surgery, progress on clinical trials in dry AMD, and more.
By Rochelle Nataloni, contributing writer
June 1, 2023
Clinical Trial Update June 2023
May 1, 2023
Polymers for Retinal Drug Delivery
By Charles D. Blizzard, Dina Akasheh, PhD, Matthew Cheung, PharmD, et al.
May 1, 2023
Clinical Trial Update May 2023
April 1, 2023
Current Status of Subretinal Delivery Devices
By Prethy Rao, MD, MPH, Edward Wood, MD, Tamer Mahmoud, MD, PhD
April 1, 2023
SUBSPECIALTY NEWS: Early anti-VEGF for DR shows no benefit, developments in gene therapy, research on IRD, and more.
By Rochelle Nataloni, contributing writer
April 1, 2023
Clinical Trial Update April 2023
March 1, 2023
A Basic Primer on Gene Therapy
By Thomas A. Ciulla, MD, MBA, Aumer Shughoury, MD
March 1, 2023
Current Challenges in Gene Therapy Trials
By Glenn C. Yiu, MD, PhD, Arshad M. Khanani, MD, MA, FASRS, Kathryn L. Pepple, MD, PhD
March 1, 2023
SUBSPECIALTY NEWS: First drug approved for ROP, PDT laser approved, inequities in ophthalmology research, and more.
By Rochelle Nataloni, contributing writer
March 1, 2023
Clinical Trial Update March 2023
February 1, 2023
SUBSPECIALTY NEWS: Methotrexate for vitreoretinal lymphoma, drugs for retinitis pigmentosa, AI technology in retina, and more.
By Rochelle Nataloni, contributing writer
February 1, 2023
CONTROVERSIES IN CARE: DRCR Network Protocol AC on Step Therapy in Retinal Disease
By Michael Colucciello, MD, Reginald Sanders, MD
February 1, 2023
Clinical Trial Update: Special Edition 2023
January 1, 2023
Noninsulin Diabetes Medication and Diabetic Retinopathy
By Lakshman Mulpuri, MD, Jayanth Sridhar, MD
January 1, 2023
Artificial Intelligence and Augmented Intelligence in Ophthalmic Practice
By Miguel A. Busquets, MD
January 1, 2023
SUBSPECIALTY NEWS: Progress toward GA drug approval, new gene therapy data, and more.
By Rochelle Nataloni, contributing writer
January 1, 2023
CLINICAL TRIAL DOWNLOAD: High-dose Aflibercept for Wet AMD and DME
By Yasha Modi, MD , PAOLO LANZETTA, MD, David Brown, MD
January 1, 2023
Clinical Trial Update January/February 2023
November 1, 2022
Artificial Intelligence for the Screening of Diabetic Retinopathy
By Priya Vakharia, MD
November 1, 2022
SUBSPECIALTY NEWS: New data presented at AAO in dry AMD, ocular oncology, gene therapy, and more.
By Rochelle Nataloni, contributing writer
November 1, 2022
Clinical Trial Update November/December 2022
October 1, 2022
SUBSPECIALTY NEWS: FDA approves Cimerli, GATHER2 GA trial meets primary endpoint, and more.
By Rochelle Nataloni, contributing writer
October 1, 2022
Clinical Trial Update October 2022
September 1, 2022
Severe Diabetic Retinopathy Without Diabetic Macular Edema
By Marisa G. Tieger, MD, Caroline R. Baumal, MD
September 1, 2022
The Latest Research Into Novel Therapies for Diabetic Macular Edema
By Abrahim A. Ahmed, BS, Hannah Khan, MPH, Tyler M. Ewing, MS, et al.
September 1, 2022
Putting Protocol V Into Practice for Patients With DME
By R. Gary Lane, MD
September 1, 2022
SUBSPECIALTY NEWS: Pegcetacoplan gets priority review, Eva Nexus injector cleared, Eylea extended dosing under review, and more.
By Rochelle Nataloni, contributing writer
September 1, 2022
Clinical Trial Update September 2022
August 1, 2022
Suprachoroidal Drug Delivery Technology
By Thomas A. Ciulla, MD, MBA, Rafael V. Andino, MSBE, MBA, Shelley Hancock, MBA
August 1, 2022
SUBSPECIALTY NEWS: Data presented on THR-149 and THR-687 for DME, pegcetacoplan NDA submitted, AREDS2 benefit confirmed, and more.
By Rochelle Nataloni, contributing writer
August 1, 2022
Clinical Trial Update Special Edition 2022
July 1, 2022
The Impact of Pregnancy on Diabetic Retinopathy and Its Implications
By Kanika Seth, Matthew W. Russell, MD, Justin C. Muste, MD, et al.
July 1, 2022
Oral Drug Pipeline for Retinal Disease
By Charles DeBoer, MD, PhD, Suzanne Michalak, MD, Ehsan Rahimy, MD
July 1, 2022
Potential Implications of Silicone Oil From Syringes
By Gustavo B. Melo, MD, PhD, FASRS
July 1, 2022
SUBSPECIALTY NEWS: RetinAI gets FDA clearance, suprachoroidal therapy update, GA trial data, and more.
By Rochelle Nataloni, contributing writer
July 1, 2022
Clinical Trial Update July/August 2022
June 1, 2022
SUBSPECIALTY NEWS: Geographic atrophy quality-of-life survey, Xipere launch, ophthalmic bevacizumab FDA application, and more.
By Rochelle Nataloni, contributing writer
June 1, 2022
Clinical Trial Update June 2022
May 1, 2022
Discordances in Perceptions of Shared Decision-making Among Patients With Retinal Diseases and Their Care Teams
By John S. Pollack, MD, W. Lloyd Clark, MD, Darius M. Moshfeghi, MD, et al.
May 1, 2022
SUBSPECIALTY NEWS: Geographic atrophy lesion growth slowed with pegcetacoplan, new data on extended-duration therapies, and more.
By Rochelle Nataloni, contributing writer
May 1, 2022
Clinical Trial Update May 2022
April 1, 2022
SUBSPECIALTY NEWS: FDA approves uveal melanoma treatment, sepofarsen fails to meet endpoints, and more.
By Rochelle Nataloni, contributing writer
April 1, 2022
Clinical Trial Update April 2022
March 1, 2022
SUBSPECIALTY NEWS: Results in suprachoroidal trial, RNA therapy for RP, Beovu in DME, and more.
By Rochelle Nataloni, contributing writer
March 1, 2022
NEW PRODUCT APPLICATIONS: Screening System Increases Diabetic Eye Disease Detection
By Karen Appold, contributing writer
March 1, 2022
Clinical Trial Update March 2022
January 1, 2022
Reimbursement for Teleophthalmology for Remote Diabetic Eye Screening
By Glenn C. Yiu, MD, PhD, Rodney Fong, Neesurg Mehta, MD
January 1, 2022
A Review of Mitochondrial Flavoprotein Fluorescence for Retinal Metabolic Imaging
By Matthew W. Russell, MD, Justin C. Muste, MD, Rishi P. Singh, MD
January 1, 2022
SUBSPECIALTY NEWS: Real-world Iluvien data, advances to program for choroidal melanoma treatment, results for at-home OCT, and more.
By Rochelle Nataloni, contributing writer
January 1, 2022
Clinical Trial Update January/February 2022
Advertisement
Recommendations
Advertisement